Erdheim-Chester Disease
Erdheim-Chester disease is a rare form of histiocytosis characterized by the abnormal proliferation of histiocytes, leading to various symptoms including bone pain, skin lesions, and organ dysfunction.
We are examining how fludeoxyglucose (18F-FDG) in PET/CT scans can help monitor juvenile patients with histiocytosis. The study will assess its safety and potential benefits for those with specific mutations.
Health conditions and diseases that the clinical trial is designed to study and treat.
Erdheim-Chester disease is a rare form of histiocytosis characterized by the abnormal proliferation of histiocytes, leading to various symptoms including bone pain, skin lesions, and organ dysfunction.
Langerhans cell sarcoma is a rare cancer that arises from Langerhans cells, which are part of the immune system, and can cause symptoms like skin rashes, bone pain, and organ involvement.
Rosai-Dorfman syndrome is a rare disorder characterized by the overproduction of histiocytes, leading to swollen lymph nodes and other systemic symptoms.
Langerhans' cell histiocytosis is a rare disease where Langerhans cells proliferate abnormally, potentially affecting various organs and causing symptoms like bone lesions and skin rashes.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.